The Full Wiki

More info on Disease-modifying antirheumatic drug

Disease-modifying antirheumatic drug: Wikis


Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.


From Wikipedia, the free encyclopedia

Disease-modifying antirheumatic drugs (DMARDs) is a category of otherwise unrelated drugs defined by their use in rheumatoid arthritis to slow down disease progression.[1] [2] The term is often used in contrast to non-steroidal anti-inflammatory drug, which refers to agents that treat the inflammation but not the underlying cause.

The term "antirheumatic" can be used in similar contexts, but without making a claim about an effect on the course.[3]



Although their use was first propagated in rheumatoid arthritis (hence their name) the term has come to include many other diseases, such as Crohn's disease, lupus erythematosus (SLE), idiopathic thrombocytopenic purpura (ITP), myasthenia gravis and various others. Many of these are autoimmune disorders, but others, such as ulcerative colitis, are not.

Some DMARDs are mild chemotherapeutics but use a side-effect of chemotherapy - immunosuppression - as its main therapeutical benefit.

The term was originally introduced to indicate a drug that reduced evidence of processes thought to underlie the disease, such as a raised erythrocyte sedimentation rate, reduced haemoglobin level, raised rheumatoid factor level and more recently, raised C-reactive protein level. More recently, the term has been used to indicate a drug that reduces the rate of damage to bone and cartilage. DMARDs can be further subdivided into traditional small molecular mass drugs synthesised chemically and newer 'biological' agents produced through genetic engineering.


Drug Mechanism
adalimumab TNF inhibitor
azathioprine Purine synthesis inhibitor
chloroquine and hydroxychloroquine (antimalarials) suppression of IL-1 & TNF-alpha, induce apoptosis of inflammatory cells and increase chemotactic factors
ciclosporin (Cyclosporin A) inhibit calcineurin
D-penicillamine Reducing numbers of T-lymphocytes etc.
etanercept TNF inhibitor
golimumab TNF inhibitor
gold salts (sodium aurothiomalate, auranofin)
infliximab TNF inhibitor
leflunomide Pyrimidine synthesis inhibitor
methotrexate (MTX) Antifolate
minocycline 5-LO inhibitor
rituximab chimeric monoclonal antibody against CD20 on B-cell surface
sulfasalazine (SSZ) suppression of IL-1 & TNF-alpha, induce apoptosis of inflammatory cells and increase chemotactic factors

Although these agents operate by different mechanisms, many of them can have similar impact upon the course of a condition.[4]

Some of the drugs can be used in combination.[5]


When treatment with DMARDs fails, cyclophosphamide or steroid pulse therapy is often used to stabilise uncontrolled autoimmune disease. Some severe autoimmune diseases are being treated with bone marrow transplants in clinical trials, usually after cyclophosphamide therapy has failed.

Combinations of DMARDs are often used together, because each drug in the combination can be used in smaller dosages than if it were given alone, thus reducing the risk of side effects.

Many patients receive an NSAID and at least one DMARD, sometimes with low-dose oral glucocorticoids. If disease remission is observed, regular NSAIDs or glucocorticoid treatment may no longer be needed. DMARDs help control arthritis but do not cure the disease. For that reason, if remission or optimal control is achieved with a DMARD, it is often continued at a maintenance dosage. Discontinuing a DMARD may reactivate disease or cause a “rebound flare,” with no assurance that disease control will be reestablished upon resumption of the medication, according to Arthritis & Rheumatism.[6]


Got something to say? Make a comment.
Your name
Your email address